Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch + Lomb Inc.

http://www.bausch.com

Latest From Bausch + Lomb Inc.

Keeping Track: Genmab/AbbVie Epkinly, Krystal’s Vyjuvek Join US FDA’s 2023 Novel Approvals List

Oncology's surprisingly low numbers this year are among the latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Will Intercept Drop OCA For NASH Following Negative FDA Panel Review?

Company tells advisory committee it is unsure of continuing on to collect Phase III outcomes data in NASH without accelerated approval, which the panel voted against.

Advisory Committees Drug Approval Standards

Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate

In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.

Deal Watch Deals

Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology

The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.

Gene Therapy Research & Development
See All

Company Information

  • Other Names / Subsidiaries
    • Bausch & Lomb
    • Bausch + Lomb Technolas
    • ISTA Pharmaceuticals, Inc. (ISTA)
    • Laboratorio Pförtner Cornealent SACIF, Waicon
    • Technolas Perfect Vision GmbH
UsernamePublicRestriction

Register